AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 JUL 9 - (NewsRx.com & NewsRx.net) -- Interleukin-12 and cholera toxin subunit B act as adjuvants to enhance mucosal and systemic immunity to human immunodeficiency virus type 1 glycoproteins.
According to recent research published in the Journal of Virology, "We have investigated the induction of protective mucosal immunity to human immunodeficiency virus type 1 (HIV-1) isolate 89.6 by intranasal (i.n.) immunization of mice with gp120 and gp140 together with interleukin-12 (IL-12) and cholera toxin subunit B (CTB) as adjuvants."
"It was found that both IL-12 and CTB were required to elicit mucosal antibody responses and that i.n. immunization resulted in increased total, immunoglobulin G1 (IgG1), and IgG2a anti-HIV-1 antibody levels in serum; increased total, IgG1, IgG2a, and IgA antibody expression in broncho-alveolar lavage fluids; and increased IgA antibody levels in vaginal washes," reported Diana I. Albu and collaborators at Albany Medical College and the Uniformed Services University of the Health Sciences in the United States. "Levels of anti-HIV-1 antibodies in both sera and secretions were higher in groups immunized with gp140 than in those immunized with gp120. However, only gp120-specific mucosal antibodies demonstrated neutralizing activity ...
Source: HighBeam Research, Adjuvants interleukin-12 and cholera toxin enhance immunity to HIV-1.